v3.25.1
Description of Organization and Summary of Significant Accounting Policies - Additional Information (Details)
$ / shares in Units, $ in Thousands
3 Months Ended
Jun. 27, 2024
USD ($)
$ / shares
shares
Mar. 31, 2025
USD ($)
Segments
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Subsidiary Sale Of Stock [Line Items]        
Accumulated deficit   $ (250,657)   $ (229,876)
Cash, cash equivalents and marketable securities   $ 197,800    
Number of operating segments | Segments   1    
Proceeds from Issuance of Common Stock   $ 0 $ 15  
Eliem Therapeutics [Member]        
Subsidiary Sale Of Stock [Line Items]        
Entity incorporation date   Oct. 18, 2018    
Distribution Agreement [Member] | Maximum [Member]        
Subsidiary Sale Of Stock [Line Items]        
Offering cost   $ 22,350    
Fair Value Inputs Level 1, 2 and 3 [Member]        
Subsidiary Sale Of Stock [Line Items]        
Fair value transfer amount   $ 0   $ 0
Private Placement [Member] | Acquisition Agreement [Member]        
Subsidiary Sale Of Stock [Line Items]        
Proceeds from issuance of common stock in initial public offering, Shares | shares 31,238,282      
Sale of Stock, Price Per Share | $ / shares $ 3.84      
Proceeds from Issuance of Common Stock $ 120,000      
Offering cost $ 300